Gualtiero Palareti, Sophie Testa, Cristina Legnani, Claudia Dellanoce, Michela Cini, Oriana Paoletti, Antonio Ciampa, Emilia Antonucci, Daniela Poli, Rossella Morandini, Maurizio Tala, Paolo Chiarugi, Rita Carlotta Santoro, Angela Maria Iannone, Erica De Candia, Pasquale Pignatelli, Elena Maria Faioni, Antonio Chistolini, Maria Del Pilar Esteban, Marco Marietta, Armando Tripodi, Alberto Tosetto
Treatment with direct oral anticoagulants (DOAC) in atrial fibrillation (AF) patients is effective and safe. However, bleeding complications still occur. Whether the measurement of DOAC levels may further improve treatment efficacy and safety is still an open issue. In the "Measure and See" (MAS) Study (#NCT03803579) venous blood was collected 15-30 days after DOAC initiation in AF patients who were then followed for one year to record the occurrence of major and clinically relevant non-major bleeding. DOAC plasma levels were measured in one laboratory, and results were kept blind to patients and treating doctors...
June 6, 2024: Blood Advances